NeoGenomics Q4 2023 Adj EPS $0.03 Beats $(0.02) Estimate, Sales $155.55M Beat $152.54M Estimate
Portfolio Pulse from Benzinga Newsdesk
NeoGenomics reported Q4 2023 adjusted EPS of $0.03, surpassing the $(0.02) estimate, with sales of $155.55M exceeding the $152.54M forecast. This represents a 12.15% increase in sales compared to the same period last year.
February 20, 2024 | 9:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NeoGenomics reported a Q4 2023 adjusted EPS of $0.03, beating estimates, with sales of $155.55M also surpassing expectations.
NeoGenomics' Q4 earnings and sales beat not only demonstrates the company's ability to surpass analyst expectations but also indicates a significant year-over-year growth in sales. This positive performance, especially in exceeding both EPS and sales forecasts, is likely to instill investor confidence and could lead to a short-term positive impact on the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100